Bevacizumab in maintenance therapy for ovarian cancer patients

Ovarian cancer is one of the most common cancers in women. Growth and extension of the tumor are associated with active neoangiogenesis regulated by vascular endothelial growth factor (VEGF). Bevacizumab decreases VEGF activity and inhibits the tumor growth.

Purpose of the study. The aim of the study was to evaluate results of bevacizumab in maintenance therapy for ovarian cancer.

Materials and methods. 26 patients with ovarian cancer received maintenance therapy with drop infusions of bevacizumab 15 mg/kg once a day for 21 days in 2014–2019 after completing chemotherapy for relapses.

Results. Bevacizumab mainterned partial response or stabilization in 76.9% of patients. The adverse events were mainly of grades 1–2 (in 88.5% of all adverse events) and could be managed by an appropriate medical correction. Hemorrhagic complications caused the cancellation of bevacizumab in one patient.

Conclusions. Bevacizumab in maintenance therapy after completing chemotherapy for ovarian cancer relapses (both platinum-sensitive and platinum-resistant) significantly improves the treatment results. The toxicity profile of bevacizumab in maintenance treatment is acceptable.

1. The state of cancer care in Russia in 2018. Ed by Kaprin A.D., Starinsky V.V., Petrova G.V. Moscow, 2019, 236 p. (In Russian).

2. Novikova EG, Moskovskaya EYu. The causes, diagnosis, and treatment of recurrent ovarian cancer. A literature review and analysis of the authors’ data. Oncology. Journal named after P. A. Herzen. 2015;4(3):59–67. (In Russian). https://doi.org/10.17116/onkolog20154359–67

3. Ledermann JA, Kristeleit RS. Optimal treatment for relapsing ovarian cancer. Ann Oncol. 2010 Oct;21 Suppl 7: vii218-vii222. https://doi.org/10.1093/annonc/mdq377

4. Thigpen T, Stuart G, du Bois A, Friedlander M, Fujiwara K, Guastalla JP, et al. Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens. Ann Oncol. 2005;16 Suppl 8: viii13-viii19. https://doi.org/10.1093/annonc/mdi962

5. Kit OI, Frantsiyants EM, Moiseenko TI, Verenikina EV, Cheryarina ND, Kozlova LS, et al. Growth factors in tussues of ovarian cancer at various stages. Medical Bulletin of the North Caucasus. 2017;12(1):48–52. (In Russian). https://doi.org/http://doi.org/10.14300/mnnc.2017.12013

6. Huang S, Robinson JB, Deguzman A, Bucana CD, Fidler IJ. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 2000 Oct 1;60(19):5334–5339.

7. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebocontrolled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012 Jun 10;30(17):2039–2045. https://doi.org/10.1200/JCO.2012.42.0505

8. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, PujadeLauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):24842496. https://doi.org/10.1056/NEJMoa1103799

9. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302–1308. https://doi.org/10.1200/JCO.2013.51.4489

10. Tyulyandin SA, Kolomiets LA, Morkhov KYu, Nechushkina VM, Pokataev IA, Rumyantsev AA, et al. Practical recommendations for drug treatment of ovarian cancer, primary peritoneal cancer and fallopian tube cancer. Malignant tumors: Practical recommendations RUSSCO. 2019;9(3s2):164–176. (In Russian). https://doi.org/10.18027/2224–5057–2019–9–3s2–164–176

11. Markman M. The Evolving Arena of Ovarian Cancer Maintenance Therapy. Oncology. 2019;97(4):202–205. https://doi.org/10.1159/000501618